Listed companies will face more strict supervision and higher responsibility to investors, especially in the pharmaceutical industry, which benefits the people's livelihood, and its development is concerned by the state. With the development of economy, people's demand for medical products has been driven, which makes the pharmaceutical industry develop rapidly. But at the same time, challenges also follow. Under the influence of the new medical reform and the wave of M & A in the national pharmaceutical industry, pharmaceutical enterprises are facing greater competition and more prominent financial risks, so it is particularly important to correctly identify and prevent the financial risks of pharmaceutical enterprises. In order to better adapt to the changes in the macro environment, pharmaceutical enterprises must fully understand the characteristics of their industry, correctly identify their own financial risks, and take certain measures to enhance their anti risk ability.
Based on the development of pharmaceutical enterprises in the past five years, this paper analyzes the financial risks of Listed Companies in the pharmaceutical industry as a whole. First of all, through a series of trends of financial ratios, four significant types of financial risks in the pharmaceutical industry are identified. Then take Haizheng pharmaceutical industry as the specific research object, using a variety of methods to analyze its specific four financial risks, and explain the reasons for the formation of each financial risk. At last, the paper puts forward some suggestions for the prevention and control of financial risks in the pharmaceutical industry from four aspects. This paper provides a reference for pharmaceutical enterprises to identify and prevent financial risks, and also provides information for investors to invest in pharmaceutical enterprises in the market.